“There have been limited advances for patients with locally advanced HNSCC, and unfortunately, these results suggest that this disease remains very challenging to treat,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “We are proud of the significant role KEYTRUDA plays in the treatment of certain later stages of HNSCC, and we are committed to investigating KEYTRUDA-based regimens for this debilitating type of cancer in earlier stages of disease. We are grateful to the patients and investigators for their participation in this study.”
This comment re "based regimes" attracts my interest .
Media, page-278
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.020(6.67%) |
Mkt cap ! $453.9M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.3¢ | 30.0¢ | $842.9K | 2.710M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 83354 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 53767 | 2 |
View Market Depth
| Last trade - 15.09pm 09/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |